Identification of tear-based protein and non-protein biomarkers: Its application in diagnosis of human diseases using biosensors

Nandi, Sandip K.; Singh, D. B.; Upadhay, Jyoti; Gupta, Neeti; Dhiman, Nayan; Mittal, Sanjeev; Mahindroo, Neeraj

doi:10.1016/j.ijbiomac.2021.10.198

Cited by 20 publications

(22 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to other body fluids, the collection of tears is easy and noninvasive, although there is currently no entirely efficient and universal method for its collection. More importantly, biomarker levels, such as those of TNF-α and VEGF in tears are comparable to those in the blood and increase with the severity of the disease ( Nandi et al, 2021 ). However, tears mainly provide exact information regarding disorders in the anterior segment.…”

Section: Biomarkersmentioning

confidence: 99%

Diabetic retinopathy: Involved cells, biomarkers, and treatments

et al. 2022

View full text Add to dashboard Cite

Diabetic retinopathy (DR), a leading cause of vision loss and blindness worldwide, is caused by retinal neurovascular unit dysfunction, and its cellular pathology involves at least nine kinds of retinal cells, including photoreceptors, horizontal and bipolar cells, amacrine cells, retinal ganglion cells, glial cells (Müller cells, astrocytes, and microglia), endothelial cells, pericytes, and retinal pigment epithelial cells. Its mechanism is complicated and involves loss of cells, inflammatory factor production, neovascularization, and BRB impairment. However, the mechanism has not been completely elucidated. Drug treatment for DR has been gradually advancing recently. Research on potential drug targets relies upon clear information on pathogenesis and effective biomarkers. Therefore, we reviewed the recent literature on the cellular pathology and the diagnostic and prognostic biomarkers of DR in terms of blood, protein, and clinical and preclinical drug therapy (including synthesized molecules and natural molecules). This review may provide a theoretical basis for further DR research.

show abstract

Section: Biomarkersmentioning

confidence: 99%

Diabetic retinopathy: Involved cells, biomarkers, and treatments

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Several recent review articles (2021–2022) refer to optical immunosensors, often among other topics of interest in the field of biosensing. Thus, some of these articles describe optical immunosensors that have been developed for various (groups of) biomolecules [ 1 , 41 , 42 ], such as COVID-19-related biomarkers [ 43 , 44 , 45 , 46 ]. Immunosensing based on optical fiber technology [ 47 , 48 ] and application of spectroscopic ellipsometry to immunosensing [ 49 ] have been presented in recent reviews.…”

Section: Newest Developments In Optical Immunosensors: Bioanalytical ...mentioning

confidence: 99%

Recent Developments in the Field of Optical Immunosensors Focusing on a Label-Free, White Light Reflectance Spectroscopy-Based Immunosensing Platform

Karachaliou

Koukouvinos

Goustouridis

et al. 2022

Sensors

View full text Add to dashboard Cite

Optical immunosensors represent a research field of continuously increasing interest due to their unique features, which can mainly be attributed to the high-affinity and specific antibodies they use as biorecognition elements, combined with the advantageous characteristics of the optical transducing systems these sensors employ. The present work describes new developments in the field, focusing on recent bioanalytical applications (2021–2022) of labeled and label-free optical immunosensors. Special attention is paid to a specific immunosensing platform based on White Light Reflectance Spectroscopy, in which our labs have gained specific expertise; this platform is presented in detail so as to include developments, improvements, and bioanalytical applications since the mid-2000s. Perspectives on the field are been briefly discussed as well, highlighting the potential of optical immunosensors to eventually reach the state of a reliable, highly versatile, and widely applicable analytical tool suitable for use at the Point-of-Care.

show abstract

“…For this reason, tears seem to be a strategic material for a new biomarkers search and for the early non-invasive diagnosis of nervous system diseases. Neurodegenerative diseases are characterized by the progressive dysfunction of the central or peripheral structures of the nervous system, and Alzheimer’s disease, Parkinson’s disease, or multiple sclerosis are examples of diseases where prompt diagnosis is very important, and biomarkers are still needed [ 6 , 7 , 8 , 9 , 10 , 11 ]. In this work, we reviewed the current state of knowledge, regarding the potential use of tears as an innovative non-invasive tool for the search for protein markers of nervous system diseases, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.…”

Section: Introductionmentioning

confidence: 99%

Tear Biomarkers in Alzheimer’s and Parkinson’s Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review)

Król-Grzymała

Sienkiewicz-Szłapka

Fiedorowicz

et al. 2022

IJMS

View full text Add to dashboard Cite

Biological material is one of the most important aspects that allow for the correct diagnosis of the disease, and tears are an interesting subject of research because of the simplicity of collection, as the well as the relation to the components similar to other body fluids. In this review, biomarkers for Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS) in tears are investigated and analyzed. Records were obtained from the PubMed and Google Scholar databases in a timeline of 2015–2022. The keywords were: tear film/tear biochemistry/tear biomarkers + diseases (AD, PD, or MS). The recent original studies were analyzed, discussed, and biomarkers present in tears that can be used for the diagnosis and management of AD, PD, and MS diseases were shown. α-synTotal and α-synOligo, lactoferrin, norepinephrine, adrenaline, epinephrine, dopamine, α-2-macroglobulin, proteins involved in immune response, lipid metabolism and oxidative stress, apolipoprotein superfamily, and others were shown to be biomarkers in PD. For AD as potential biomarkers, there are: lipocalin-1, lysozyme-C, and lacritin, amyloid proteins, t-Tau, p-Tau; for MS there are: oligoclonal bands, lipids containing choline, free carnitine, acylcarnitines, and some amino acids. Information systematized in this review provides interesting data and new insight to help improve clinical outcomes for patients with neurodegenerative disorders.

show abstract

Identification of tear-based protein and non-protein biomarkers: Its application in diagnosis of human diseases using biosensors

Cited by 20 publications

References 96 publications

Diabetic retinopathy: Involved cells, biomarkers, and treatments

Diabetic retinopathy: Involved cells, biomarkers, and treatments

Recent Developments in the Field of Optical Immunosensors Focusing on a Label-Free, White Light Reflectance Spectroscopy-Based Immunosensing Platform

Tear Biomarkers in Alzheimer’s and Parkinson’s Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review)

Contact Info

Product

Resources

About